121 related articles for article (PubMed ID: 26573429)
1. Smac mimetic‑induced caspase‑independent necroptosis requires RIP1 in breast cancer.
Jin G; Lan Y; Han F; Sun Y; Liu Z; Zhang M; Liu X; Zhang X; Hu J; Liu H; Wang B
Mol Med Rep; 2016 Jan; 13(1):359-66. PubMed ID: 26573429
[TBL] [Abstract][Full Text] [Related]
2. Induction of Necroptosis in Human Breast Cancer Drug-Resistant Cells by SMAC Analog LCL161 After Caspase Inhibition Requires RIP3.
Jin G; Liu Y; Xu P; Jin G
Pharmazie; 2019 Jun; 74(6):363-368. PubMed ID: 31138375
[TBL] [Abstract][Full Text] [Related]
3. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
Hannes S; Abhari BA; Fulda S
Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
[TBL] [Abstract][Full Text] [Related]
4. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
5. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
de Almagro MC; Goncharov T; Newton K; Vucic D
Cell Death Dis; 2015 Jun; 6(6):e1800. PubMed ID: 26111062
[TBL] [Abstract][Full Text] [Related]
6. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
7. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of caspase inhibitors on TNF-induced necroptosis.
Sawai H
Biochem Biophys Res Commun; 2013 Mar; 432(3):451-5. PubMed ID: 23410748
[TBL] [Abstract][Full Text] [Related]
9. [Effects of LCL161, a Smac mimetic on the proliferation and apoptosis in hepatocellular carcinoma cells].
Ren K; Ma L; Chong D; Zhang Z; Zhou C; Liu H; Zhao S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Sep; 41(9):898-904. PubMed ID: 27640787
[TBL] [Abstract][Full Text] [Related]
10. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells.
Jin G; Wang K; Liu Y; Liu X; Zhang X; Zhang H
Anticancer Agents Med Chem; 2020; 20(6):687-699. PubMed ID: 32053082
[TBL] [Abstract][Full Text] [Related]
12. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
[TBL] [Abstract][Full Text] [Related]
13. Loss of FADD and Caspases Affects the Response of T-Cell Leukemia Jurkat Cells to Anti-Cancer Drugs.
Mrkvová Z; Portešová M; Slaninová I
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800107
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of RIP1 by 2-deoxy-D-glucose sensitizes breast cancer cells to TRAIL-induced apoptosis.
Huang YY; Liu H; Li Y; Pu LJ; Jiang CC; Xu JC; Jiang ZW
Eur J Pharmacol; 2013 Apr; 705(1-3):26-34. PubMed ID: 23499682
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
[TBL] [Abstract][Full Text] [Related]
16. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.
Geserick P; Hupe M; Moulin M; Wong WW; Feoktistova M; Kellert B; Gollnick H; Silke J; Leverkus M
J Cell Biol; 2009 Dec; 187(7):1037-54. PubMed ID: 20038679
[TBL] [Abstract][Full Text] [Related]
17. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.
Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S
Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.
Ramakrishnan V; Painuly U; Kimlinger T; Haug J; Rajkumar SV; Kumar S
Leukemia; 2014 Jul; 28(7):1519-28. PubMed ID: 24402161
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound.
Cheung HH; Mahoney DJ; Lacasse EC; Korneluk RG
Cancer Res; 2009 Oct; 69(19):7729-38. PubMed ID: 19773432
[TBL] [Abstract][Full Text] [Related]
20. RIP1-dependent Bid cleavage mediates TNFα-induced but Caspase-3-independent cell death in L929 fibroblastoma cells.
Chen G; Cheng X; Zhao M; Lin S; Lu J; Kang J; Yu X
Apoptosis; 2015 Jan; 20(1):92-109. PubMed ID: 25398540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
